Ione Corrêa

Ione Corrêa

Auto-generated profile, based on publicly available information

Ione Corrêa

Medical School, São Paulo State University (Unesp), Botucatu 18618-687, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2012 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
PBPaulo José Fortes Villas Boas
Paulo José Fortes Villas Boas
RSRegina Stella Spagnuolo
Regina Stella Spagnuolo
AKAmélia Kamegasawa
Amélia Kamegasawa
LBLeandro Gobbo Braz
Leandro Gobbo Braz
AVAdriana Polachini Valle
Adriana Polachini Valle
RDRegina El Dib
Regina El Dib

29 May 2022 in Phytotherapy Research
Verified
Journal Article
Closed access
Gabriel Davi MarenaGabriel Davi Marena
Gabriel Davi Marena
MRMatheus Aparecidos Dos Santos Ramos
Matheus Aparecidos Dos Santos Ramos
GCGabriela Corrêa Carvalho
Gabriela Corrêa Carvalho
JJJosé Alberto Paris Junior
José Alberto Paris Junior
FRFlávia Resende
Flávia Resende
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

5 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
GCGabriela Corrêa Carvalho
Gabriela Corrêa Carvalho
Gabriel Davi MarenaGabriel Davi Marena
Gabriel Davi Marena
GLGabriela Ricci Leonardi
Gabriela Ricci Leonardi
RSRafael Miguel Sábio
Rafael Miguel Sábio
ICIone Corrêa
Ione Corrêa
TBTais Maria Bauab
Tais Maria Bauab
Commonly found colonizing the human microbiota, Candida albicans is a microorganism known for its ability to cause infections, mainly in the vulvovaginal region known as vulvovaginal candidiasis (VVC). This pathology is, in fact, one of the main C. albicans clinical manifestations, changing from a colonizer to a pathogen. The increase in VVC cases and limited antifungal therapy make C. albicans an increasingly frequent risk in women’s lives, especially in immunocompromised patients, pregnant women and the elderly. Therefore, it is necessary to develop new therapeutic options, especially those involving natural products associated with nanotechnology, such as lycopene and mesoporous silica nanoparticles. From this perspective, this study sought to assess whether lycopene, mesoporous silica nanoparticles and their combination would be an attractive product for the treatment of this serious disease through microbiological in vitro tests and acute toxicity tests in an alternative in vivo model of Galleria mellonella. Although they did not show desirable antifungal activity for VVC therapy, the present study strongly encourages the use of mesoporous silica nanoparticles impregnated with lycopene for the treatment of other human pathologies, since the products evaluated here did not show toxicity in the in vivo test performed, being therefore, a topic to be further explored.

1 May 2017 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
LCLarissa Pierri Carvalho
Larissa Pierri Carvalho
AAArnav Agarwal
Arnav Agarwal
FKFlávio T. Kashiwagi
Flávio T. Kashiwagi
ICIone Corrêa
Ione Corrêa
JPJosé Eduardo Guimarães Pereira
José Eduardo Guimarães Pereira
RDRegina El Dib
Regina El Dib

1 September 2015 in Clinics
Verified
Journal Article
Open access
RDRegina El Dib
Regina El Dib
EJEliane Chaves Jorge
Eliane Chaves Jorge
AKAmélia Kamegasawa
Amélia Kamegasawa
SDSolange Ramires Daher
Solange Ramires Daher
RSRegina Stella Spagnuolo
Regina Stella Spagnuolo
PJPaulo Do Nascimento Junior
Paulo Do Nascimento Junior
We refer to the effectiveness (known as pragmatic or real world) and efficacy (known as explanatory or desired or ideal world) of interventions. However, these terms seem to be randomly chosen by investigators who design clinical trials and do not always reflect the true purpose of the study. A pragmatic-explanatory continuum indicator summary tool was thus developed with the aim of identifying the characteristics of clinical trials that distinguish between effectiveness and efficacy issues. We verified whether clinical trials used the criteria proposed by the indicator summary tool, and we categorized these clinical trials according to a new classification. A systematic survey of randomized clinical trials was performed. We added a score ranging from 0 (more efficacious) to 10 (more effective) to each domain of the indicator summary tool and proposed the following classifications: high efficacy (<25), moderate efficacy (25-50), moderate effectiveness (51-75), and high effectiveness (<75). A total of 844 randomized trials were analyzed. No analyzed trials used the criteria proposed by the indicator summary tool. Approximately 44% of the trials were classified as having moderate effectiveness, and 43.82% were classified as having moderate efficacy. Most clinical trials used the term "efficacy" to illustrate the application of results in clinical practice, but the majority of those were classified as having moderate effectiveness according to our proposed score. The classification based on the 0-100 score is still highly subjective and can be easily misunderstood in all domains based on each investigator's own experiences and knowledge.

9 October 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ICIone Corrêa
Ione Corrêa
DMDonna Moralejo
Donna Moralejo
PBPasqual Barretti
Pasqual Barretti
RDRegina P El Dib
Regina P El Dib